Kinnate Biopharma Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD from Q4 2020 to Q4 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
-
Summary
-
Kinnate Biopharma Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q4 2020 to Q4 2023.
- Kinnate Biopharma Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending December 31, 2023 was $40.4M, a 18.4% increase year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)